Vancouver, British Columbia - April 11, 2012 (InvestorIdeas.com Newswire) Sirona Biochem Corp. ( TSX-V: SBM , OTC: SRBCF, Frankfurt: ZSB), announced today its abstract application to present a scientific poster at the 2012 Protein Engineering Summit (PEGS) has been accepted. Sirona Biochem's scientific poster has been selected to be on display during the “Difficult to Express Proteins” track April 30 to May 1, 2012.
The Eighth Annual PEGS conference, to be held April 30 - May 4, 2012 in Boston, MA, brings together an estimated 1,400 international decision makers in pharmaceutical, biotechnology, academia and public healthcare and focuses on the latest scientific innovations in protein engineering.
Sirona Biochem's scientific poster at the PEGS conference will describe the use of its new inducer, SBM-TFC-358, and how it may be effective at improving recombinant protein yields. The poster will also include results from the latest study demonstrating the effectiveness of SBM-TFC-358 on a recalcitrant protein and comparing the compound against a widely used inducer, IPTG.
Additional studies are being conducted to further characterize SBM-TFC-358 and prepare it for commercialization.
A copy of the poster will be made available on the company's website at www.sironabiochem.com after the conference.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Published at the Investorideas.com Newswire
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp
Disclosure- Investorideas.com and its affiliate news and email partners were compensated six thousand for news distribution and publishing online and to optin subscribers